Diabetes drug could help weak hearts after bypass surgery

NCT ID NCT07601867

Recruiting now Disease control Sponsor: Pyatigorsk City Clinical Hospital Number 1 Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether the diabetes drug dapagliflozin can improve how well the right side of the heart works after off-pump coronary bypass surgery. Researchers will measure heart function in 72 patients with weak hearts before and after 6 months of taking the drug. The goal is to see if the drug helps the heart pump blood more efficiently.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin (a diabetes drug that may also help the heart)
What this could lead to: If successful, this could show that dapagliflozin helps the heart pump more efficiently after bypass surgery, pointing toward a new use for this drug.
What could go wrong: This is a small, early observational study with no control group, so results may not be conclusive. The drug may not improve heart function as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERIAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERIAL DISEASE HEART FAILURE

Contacts and locations

Locations

Pyatigorsk City Clinical Hospital Number 1
RECRUITING

Pyatigorsk, Stavropol Kray, 357500, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.